# NCT04644770 (NCT04644770)

> A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04644770
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Prostatic Neoplasms; Adenocarcinoma
- Interventions: JNJ-69086420; JNJ-78278343; Stereotactic body radiation therapy
- Enrollment: 144
- Primary outcome: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
- Primary outcome: Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
- Primary outcome: Number of Participants with AEs by Severity

## Indexed commentary on NCT04644770 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04644770